What to Expect From Biogen's $2.3 Billion Shopping Spree

After selling its stake in a biosimilar joint venture with Samsung Biologics, Biogen (NASDAQ:BIIB) has reportedly now brought Goldman Sachs on board to identify potential acquisition targets. In this segment from "This Week in Healthcare," Motley Fool contributors Brian Orelli and Keith Speights review some of the pharmaceutical companies on Biogen's short list.